3 completed, 1 not yet recruiting, 1 recruiting. 5 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
Follow Autoimmune Hepatitis: new trials by email Literature Review of Autoimmune Hepatitis trials Research Report on Autoimmune Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis Inebilizumab, Placebo, Standard of Care - Autoimmune Hepatitis, AIH | Phase 3 | Recruiting | Amgen | 180 | 2026-12-18 | 2026-11-03 |
| Induction of Remission in Autoimmune Hepatitis With Azathioprine vs. MMF Mycophenolate Mofetil + Prednisolone Participants will receive mycophenolate mofetil in combination., Azathioprine + Prednisolone - Autoimmune Hepatitis | Phase 2 / Phase 3 | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 108 | 2024-11-01 | 2024-11-07 |
| ADCC Mediated B-Cell dEpletion and BAFF-R Blockade VAY736, Placebo - Autoimmune Hepatitis | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 68 | 2018-02-15 | 2026-02-19 |
| Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis Cyclosporine-A - Autoimmune Hepatitis | Phase 3 | Completed | Tehran University of Medical Sciences | 55 | 2005-12-01 | 2019-07-19 |
| Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis budesonide, prednisone - Autoimmune Hepatitis | Phase 2 / Phase 3 | Completed | Dr. Falk Pharma GmbH | 208 | 2001-03-01 | 2019-05-07 |
Autoimmune Diseases (5) · Digestive System Diseases (5) · Hepatitis (5) · Hepatitis, Chronic (5) · Immune System Diseases (5) · Liver Diseases (5)
Azathioprine (1) · Budesonide (1) · Cyclosporins (1) · Mycophenolic Acid (1) · Prednisolone (1) · Prednisone (1) · Standard of Care (1) · ianalumab (1) · inebilizumab (1)
Amgen (1) · Dr. Falk Pharma GmbH (1) · Institute of Liver and Biliary Sciences, India (1) · Novartis Pharmaceuticals (1) · Tehran University of Medical Sciences (1)
Germany (3) · Belgium (2) · Canada (2) · United States (2) · Argentina (1) · China (1) · Czechia (1) · France (1) · Hungary (1) · Iran (1) · Italy (1) · Japan (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Michael M Manns, Professor (1)
PMID 20600032, PMID 23810723, PMID 35179437, PMID 37722131
2023 (1), 2025 (1)